Rivercell Raises €22M to Build Cell-Response World Model
Rivercell raised €22M Seed led by HV to scale its proprietary data generation platform and AI Virtual Cell program.
The big picture: Rivercell, a Paris-based BioTech and AI company, has launched today out of stealth with a €22 million Seed round. The company is building proprietary cell-response data infrastructure and a world model that predicts how human cells respond to treatment. Rivercell will use the investment to scale its data generation platform, expand its Paris wet lab, and launch its AI Virtual Cell program.
Why it matters:
- Accelerating Drug Discovery: Rivercell’s AI world model aims to fundamentally change drug discovery by predicting cellular responses in silico, potentially reducing the years and billions of euros currently spent on R&D.
- Proprietary Data Advantage: The company’s in-house platform generates massive, high-quality, multimodal single-cell data, which is critical for training advanced AI models that can accurately simulate complex biological processes.
- European AI Leadership: This funding round highlights Europe’s growing investment in the intersection of AI and biology, contributing to the continent’s strategic position in these critical fields.
How it works:
- Data Engine: Rivercell’s proprietary platform produces interventional, time-resolved, and multimodal single-cell data at scale, forming the foundation for its AI models.
- AI Virtual Cell (AIVC): The AIVC is a ‘world model’ designed to predict how human cells respond to drugs or genetic changes, aiming to reduce the need for extensive physical wet-lab experiments.
- Full-Stack Approach: The company combines novel data generation, automated wet labs, and advanced AI world models to create a comprehensive system for understanding and engineering biology.
The catch: The AI-driven drug discovery sector is highly competitive, with numerous European startups securing significant funding for similar approaches, including automated labs and patient-derived data platforms. Rivercell will need to demonstrate clear differentiation and superior predictive power to stand out in a crowded market and justify its ‘world model’ ambition.
Key Facts
- Company: Rivercell
- Amount: €22M
- Round: Seed
- Investors: HV (lead), HCVC, Alven, Bpifrance Digital Venture
- Founders: Yann Fleureau, Eric Durand
- Sector: AI-Powered Drug Discovery Infrastructure
- Headquarters: Paris, France
Funding Weekly
Every AI funding round we reported last week: the totals, the biggest deals and what they add up to. Weekly · Tuesdays.